Tweets
Brenda McShan: The Creative Heart of RheumNow
A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.
https://t.co/b4fmN1bpFG https://t.co/p4jCPfT5uZ
Dr. John Cush @RheumNow ( View Tweet )
1 hour 4 minutes ago
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from https://t.co/V10S4oVFsv. Updates on tofacitinib, CAR-T therapy and AI.
https://t.co/DNWh7taaN6 https://t.co/4r5fuooqWn
Dr. John Cush @RheumNow ( View Tweet )
2 hours 34 minutes ago
EULAR26: Updates in SLE and APS
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
https://t.co/DP7gPvlGhU https://t.co/imN6Xb7QGT
Dr. John Cush @RheumNow ( View Tweet )
4 hours 4 minutes ago
My take on diet based intervention studies presented at #EULAR2026
It's all in the title: Diet as a DMARD? The Evidence Is Still Hard to Swallow
https://t.co/JDVlaOsC6w
Head to @RheumNow.com to have a read and for more faculty articles! https://t.co/luV3zZTKOU https://t.co/xHq23oYpjY
Dr. John Cush @RheumNow ( View Tweet )
18 hours 5 minutes ago
Is it all over for avacopan? #Vasculitis
https://t.co/1sFUidC6Cw
Rheuma Doc @LastManStand85 ( View Tweet )
22 hours 34 minutes ago
RT @jiharheum : ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. #EULAR2026 POS0255
Dr. John Cush @RheumNow ( View Tweet )
23 hours 4 minutes ago
RT @drminidey
#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile.
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Which is NOT a key feature of inflammatory back pain: relief with activity; morning stiffness; age under 40 years; unilateral pain? Test your knowledge in this week's RheumIQ quiz at https://t.co/z8mLbcgE5D. https://t.co/tOdPfEBJa4
Dr. John Cush @RheumNow ( View Tweet )
1 day 2 hours ago
Obexelimab in IgG4-Related Disease: INDIGO Trial
Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026.
https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn
Dr. John Cush @RheumNow ( View Tweet )
1 day 3 hours ago
2026 Guidelines for the Treatment of Axial Spondyloarthritis
New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush @RheumNow ( View Tweet )
1 day 17 hours ago
Self-Directed Cognitive Behavioral Therapy for Chronic Pain
Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?
https://t.co/P2DDvCiLNL https://t.co/hyAArEG6V1
Dr. John Cush @RheumNow ( View Tweet )
1 day 19 hours ago
EULAR26: Pitfalls in T2T
EULAR recommends T2T strategy in the management of RA and other RMD aiming for clinical remission or low disease activity guided by frequent monitoring and prompt therapy adjustments. But real-world daily implementation in remains poorly investigated. https://t.co/V6mCcdmyJz
Dr. John Cush @RheumNow ( View Tweet )
1 day 22 hours ago
